# A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes

Source: https://onco.cc/trials/nct06712680/  
OnCo record `nct06712680` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Test Product HYP-6589 in advanced solid tumours, run by Sichuan Huiyu Pharmaceutical Co., Ltd, now recruiting.

## Summary

A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes is a phase 1/2 interventional study registered as NCT06712680 by Sichuan Huiyu Pharmaceutical Co., Ltd, with 115 participants planned, started 2024-11-27 and due to reach its primary completion in 2028-04-10. Interventions recorded: Test Product HYP-6589.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06712680
- Phase: 1/2
- Setting: A Phase I/II , Open-label, Multi-center, Multi-cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HYP-6589 Monotherapy in Advanced Solid Tumors and Combination With Tyrosine Kinase Inhibitors in Patients With Advanced NSCLC With Target-driven Gene Positivity
- Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd
- Enrolled: 115

## Sources

- ClinicalTrials.gov NCT06712680: https://clinicaltrials.gov/study/NCT06712680

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06712680.json